$1.88
21.29%
Nasdaq, Sep 18, 03:30 pm CET

ImmunoPrecise Antibodies Ltd Stock price

$1.73
-0.84 32.68% 1M
+1.29 293.27% 6M
+1.32 320.21% YTD
+1.06 156.30% 1Y
-3.28 65.47% 3Y
-7.54 81.34% 5Y
+1.63 1,547.62% 10Y
+1.55 861.11% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
-0.15 7.98%

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$2.0m
Cash
$7.7m
Shares outstanding
46.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
53.2%
Return on Equity
-128.0%
ROCE
-34.9%
ROIC
-41.0%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$17.8m | $21.1m
EBITDA
$-7.6m | -
EBIT
$-9.0m | $-4.1m
Net Income
$-21.9m | $-5.1m
Free Cash Flow
$-5.2m
Growth (TTM | estimate)
Revenue
0.0% | 18.8%
EBITDA
6.2% | -
EBIT
12.2% | 54.1%
Net Income
-11.3% | 76.9%
Free Cash Flow
-27.9%
Margin (TTM | estimate)
Gross
55.3%
EBITDA
-42.5% | -
EBIT
-50.5%
Net
-123.3% | -24.0%
Free Cash Flow
-29.4%
More
EPS
$-0.5
FCF per Share
$-0.1
Short interest
1.0%
Employees
87
Rev per Employee
$200.0k
Show more

Is ImmunoPrecise Antibodies Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

ImmunoPrecise Antibodies Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:

Buy
83%
Hold
17%

Financial data from ImmunoPrecise Antibodies Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
18 18
0% 0%
100%
- Direct Costs 7.96 7.96
12% 12%
45%
9.83 9.83
12% 12%
55%
- Selling and Administrative Expenses 14 14
1% 1%
78%
- Research and Development Expense 3.59 3.59
23% 23%
20%
-7.57 -7.57
6% 6%
-43%
- Depreciation and Amortization 1.41 1.41
34% 34%
8%
EBIT (Operating Income) EBIT -8.98 -8.98
12% 12%
-50%
Net Profit -22 -22
11% 11%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunoPrecise Antibodies Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunoPrecise Antibodies Ltd Stock News

Neutral
Business Wire
19 days ago
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to HYFT. The new identity conveys the Company's evolution into a Bio-Native AI platform business...
Neutral
Business Wire
20 days ago
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor m...
Neutral
Business Wire
26 days ago
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope usin...
More ImmunoPrecise Antibodies Ltd News

Company Profile

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Head office Canada
CEO Jennifer Bath
Employees 87
Founded 1983
Website www.ipatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today